[go: up one dir, main page]

SMT201900548T1 - Biotina per il trattamento di neuropatie demielinizzanti - Google Patents

Biotina per il trattamento di neuropatie demielinizzanti

Info

Publication number
SMT201900548T1
SMT201900548T1 SM20190548T SMT201900548T SMT201900548T1 SM T201900548 T1 SMT201900548 T1 SM T201900548T1 SM 20190548 T SM20190548 T SM 20190548T SM T201900548 T SMT201900548 T SM T201900548T SM T201900548 T1 SMT201900548 T1 SM T201900548T1
Authority
SM
San Marino
Prior art keywords
biotin
demyelinating neuropathies
treating demyelinating
treating
neuropathies
Prior art date
Application number
SM20190548T
Other languages
English (en)
Inventor
Frédéric Sedel
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201900548(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of SMT201900548T1 publication Critical patent/SMT201900548T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Ceramics (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
  • Farming Of Fish And Shellfish (AREA)
SM20190548T 2015-03-26 2016-03-25 Biotina per il trattamento di neuropatie demielinizzanti SMT201900548T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
EP16713833.8A EP3273957B1 (en) 2015-03-26 2016-03-25 Biotin for treating demyelinating neuropathies
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
SMT201900548T1 true SMT201900548T1 (it) 2019-11-13

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20190548T SMT201900548T1 (it) 2015-03-26 2016-03-25 Biotina per il trattamento di neuropatie demielinizzanti

Country Status (24)

Country Link
US (2) US10357480B2 (it)
EP (2) EP3072513A1 (it)
JP (1) JP6752874B2 (it)
KR (1) KR20170131543A (it)
CN (2) CN107405335A (it)
AU (1) AU2016238759B2 (it)
BR (1) BR112017020408A2 (it)
CA (1) CA2980660A1 (it)
CY (1) CY1122374T1 (it)
DK (1) DK3273957T3 (it)
EA (1) EA034394B1 (it)
ES (1) ES2748354T3 (it)
HR (1) HRP20191491T1 (it)
HU (1) HUE046116T2 (it)
IL (1) IL254619B (it)
LT (1) LT3273957T (it)
MA (1) MA41809B1 (it)
ME (1) ME03567B (it)
PL (1) PL3273957T3 (it)
PT (1) PT3273957T (it)
RS (1) RS59149B1 (it)
SI (1) SI3273957T1 (it)
SM (1) SMT201900548T1 (it)
WO (1) WO2016151132A1 (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
CN113164278B (zh) * 2018-12-11 2024-11-01 马优斯珀茨澳大利亚私人有限公司 粘合垫
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
AU2003277006C1 (en) 2002-09-27 2010-04-01 Biogen Idec Ma Inc. Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
EP2515863A2 (en) 2009-12-23 2012-10-31 Lupin Limited Slow release pharmaceutical compositions of iloperidone
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
US10654916B2 (en) * 2011-04-21 2020-05-19 The Regents Of The University Of California, A California Corporation Compositions and methods for the treatment of neuromyelitis optica
CN104039148A (zh) * 2011-07-13 2014-09-10 赛特凯恩蒂克公司 组合als疗法
WO2014177286A1 (en) 2013-04-29 2014-11-06 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
HRP20191491T1 (hr) 2019-11-15
JP6752874B2 (ja) 2020-09-09
KR20170131543A (ko) 2017-11-29
WO2016151132A1 (en) 2016-09-29
US20190314342A1 (en) 2019-10-17
AU2016238759B2 (en) 2020-08-06
CN107405335A (zh) 2017-11-28
BR112017020408A2 (pt) 2018-06-05
EP3273957A1 (en) 2018-01-31
MA41809A (fr) 2018-01-30
US20180125825A1 (en) 2018-05-10
DK3273957T3 (da) 2019-11-11
LT3273957T (lt) 2019-11-11
MA41809B1 (fr) 2019-12-31
ES2748354T3 (es) 2020-03-16
EA034394B1 (ru) 2020-02-04
CA2980660A1 (en) 2016-09-29
EP3273957B1 (en) 2019-08-14
CY1122374T1 (el) 2021-01-27
EA201792124A1 (ru) 2018-04-30
PT3273957T (pt) 2019-09-18
HUE046116T2 (hu) 2020-02-28
AU2016238759A1 (en) 2017-10-05
SI3273957T1 (sl) 2019-11-29
US10357480B2 (en) 2019-07-23
PL3273957T3 (pl) 2020-01-31
JP2018512451A (ja) 2018-05-17
EP3072513A1 (en) 2016-09-28
CN111973592A (zh) 2020-11-24
IL254619B (en) 2020-03-31
IL254619A0 (en) 2017-11-30
RS59149B1 (sr) 2019-09-30
NZ735528A (en) 2021-09-24
ME03567B (me) 2020-07-20

Similar Documents

Publication Publication Date Title
IL244096A0 (en) Reinforcement for moving an object
HK1258823A1 (zh) 用於治療肌營養不良的方法
GB201500989D0 (en) Process
HK1244217A1 (zh) 用於治療蛋白質病的方法
IL256116B (en) geometric
GB201502894D0 (en) Process
IL278247B (en) mct4 inhibitors to treat the disease
GB201502893D0 (en) Process
HK1255871A1 (zh) 用於治療骨髓瘤的賽度替尼
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
GB201502137D0 (en) Treatment
HK1250649A1 (zh) 用於治療白血病的抗-s100a8
GB201501952D0 (en) Process
GB201522243D0 (en) Treatment
HK1255481A1 (zh) 用於治療hcv的方法
GB201501953D0 (en) Process
GB201500990D0 (en) Process
GB201503635D0 (en) Process
SI3273957T1 (sl) Biotin za zdravljenje demielinizacijske nevropatije
GB201502814D0 (en) Process
GB201501423D0 (en) Process
GB201508841D0 (en) Treatment
GB201503607D0 (en) Process
GB201503008D0 (en) Treatment
GB201503636D0 (en) Process